What is perseris?

Perseris is an extended-release injectable form of risperidone used to treat schizophrenia in adults.

What is the dosing schedule for Perseris?
Perseris is given as a monthly intramuscular injection into the abdomen or upper arm after the first two months. The available doses are 90 mg and 120 mg, and patients must establish tolerability with oral risperidone before starting the long-acting formulation.

How is Perseris different from other risperidone products?
Unlike daily oral risperidone tablets or the biweekly Risperdal Consta injection, Perseris delivers medication continuously for a full month using its proprietary polymer-based delivery system. This removes the need for daily pills and reduces the frequency of clinic visits compared with biweekly dosing.

When does the Perseris patent expire?
DrugPatentWatch.com lists the key U.S. composition-of-matter patent for Perseris as expiring in 2031, with additional formulation patents extending market protection into the mid-2030s.

Can generic versions of Perseris be launched before patent expiry?
No. The remaining patent life blocks generic entry until the listed patents expire, unless a successful patent challenge or settlement occurs earlier.

Who makes Perseris?
Perseris is manufactured and marketed by Indivior.

What side effects do patients report most often?
Common patient concerns include injection-site pain, weight gain, and drowsiness. These effects are similar to those seen with other risperidone products, but the injection itself can cause local discomfort that lasts several days.